View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

       

Latest Headlines

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/31/2020 4:04:34 PM

During the quarter, Regeneus Ltd (ASX:RGS) received notification from Kyocera Corporation (TYO:6971) that its lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis (Progenza OA) had passed Kyocera's due diligence process.

Read Full Article

News

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/31/2020 4:04:34 PM

During the quarter, Regeneus Ltd (ASX:RGS) received notification from Kyocera Corporation (TYO:6971) that its lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis (Progenza OA) had passed Kyocera's due diligence process.

Read Full Article

Regeneus Ltd (ASX:RGS) Progenza OA Kyocera Negotiations Update

🕔7/28/2020 9:34:41 AM 398

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today provides an update on its negotiations with Kyocera Corporation (TYO:6971) for a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis in Japan

Read Full Article

Regeneus Ltd (ASX:RGS) Featured in Morgans' 'Under The Microscope' Podcast series

🕔7/11/2020 9:00:15 AM 1032

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, was recently featured in the 'Under the Microscope' podcast series from Morgans.

Read Full Article

Regeneus Ltd (ASX:RGS) Director Resignation

🕔6/4/2020 10:53:55 AM 1050

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.

Read Full Article

Regeneus Ltd (ASX:RGS) Kyocera completes Progenza Due Diligence

🕔5/18/2020 8:39:52 AM 1402

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has received notification that Kyocera Corporation (TYO:6971) has completed its due diligence process on its lead stem cell platform technology Progenza for treatment of Knee Osteoarthritis (Progenza OA).

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/29/2020 10:35:36 AM 1483

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its quarterly cashflow report and review of operational activities for the period ending 31 March 2020.

Read Full Article

Regeneus Ltd (ASX:RGS) to be granted new key Progenza patent in U.S.

🕔3/23/2020 9:42:44 AM 1535

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's lead stem cell platform technology, Progenza, in the U.S.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives A$1.6M Milestone Payment from Kyocera

🕔3/20/2020 9:49:10 AM 1693

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, Today received a non-refundable milestone payment of 100,000,000 JPY (approx. A$1.6M) from Kyocera Corporation (TYO:6971) as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.

Read Full Article

Regeneus Ltd (ASX:RGS) Signs MOU with Kyocera Corporation

🕔3/2/2020 10:23:45 AM 2030

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has signed a non-binding MOU with Kyocera Corporation (Kyocera, TYO:6971).

Read Full Article

Regeneus Ltd (ASX:RGS) Half-Year Results & Business Update

🕔2/28/2020 4:16:21 PM 1783

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its Half-Year Financial Results and Appendix 4D for the period ended 31 December 2019 (H1 FY20).

Read Full Article
###

143,921 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 331) (Last 30 Days: 1021) (Since Published: 67936) 

Company Data

    Headquarters
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports